[1] 姚洁洁,张静雯,朱樱,等.乳腺导管内癌微浸润癌分子生物标志物的表达及其与超声表现的相关性[J].诊断学理论与实践,2014,13(6):588-592.
[2] 徐明,叶辉,叶曼娜,等. 乳腺导管内癌伴微浸润的病理和免疫组织化学特征分析[J].中国临床医学,2015,22(2):224-227.
[3] 游希,陶山,王少璐. 乳腺导管内癌及其微浸润与乳腺浸润性导管癌的超声及病理特征[J].海南医学,2017,28(10):1638-1640.
[4] 江科,薛晓红,黎伟.乳腺导管内癌及乳腺导管内癌伴微浸润182例患者的临床分析[J].肿瘤,2013,33(6):546-549.
[5] 李爽,郎冠天,余科达,等.乳腺导管原位癌和乳腺导管原位癌伴微浸润的分子分型差异性研究[J].中国癌症杂志,2018,7(5):383-388.
[6] Porter L H, Hashimoto K, Lawrence M G, et al. Intraductal carcinoma of the prostate can evade androgen-deprivation, with emergence of castrate tolerant cells[J].BJU International,2017,121(Suppl 4):971-978.
[7] Zhang Y,Chen Z,Bao Y,et al.Invasive neuroendocrine carcinoma of the breast:a prognostic research of 107 Chinese patients[J].Neoplasma,2013, 60(2):215-22.
[8] Gasparrini S,Cimadamore A,Mazzucchelli R,et al.Pathology and molecular updates in tumors of the prostate:towards a personalized approach[J].Expert Rev Mol Diagn,2017,17(8):781-789.
[9] Kristiansen G,Varma M,Seitz G.Intraductal carcinoma of the prostate[J].Pathologe,2016,37(1):27-32.
[10] Liza M Q,Laura C C.Assessing intraductal proliferations in breast core needle biopsies[J].Diagnostic Histopathology,2018, 24(2):49-57.
[11] Niinikoski L,Hukkinen K,Leidenius M H K,et al.Breast Lesion Excision System in the diagnosis and treatment of intraductal papillomas-A feasibility study[J].Eur J Surg Oncol,2018,44(1):59-66. |
